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ABSTRACT
A disruption ofthe dynamic equilibrium ofthe healthy vagina may have significant sequelae, leading
to chronic or serious conditions. Therefore, all cases ofvaginitis should be accurately diagnosed and
appropriately treated. (C) 1993 Wiley-Liss, Inc.
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aginitis is probably the most common reason
for patients seeking a physician’s care for prob-
lems related to the reproductive tract. Vaginitis is
estimated to be responsible for 10% of such office
visits. Thomason et al.
2 reported that bacterial
vaginosis accounted for 31.1% of the cases seen in
their ambulatory practice. In addition, they found
that 23.9% of these cases were due to yeast, 12.9%
due to human papillomavrius (HPV), 8.9% to un-
known causes, 6.1% to bacterial vaginitis, and 2.7%
to atrophic vaginitis.
Although vaginitis is sometimes considered to be
nothing more than a nuisance, it has been impli-
cated in significant sequelae in perinatal, postpar-
tum, and postgynecologic surgery patients. There
is some disagreement on a direct cause-and-effect
relationship between the presence of vaginitis and
subsequent morbidity in the obstetric and gyneco-
logic patient, but it stands to reason that a vaginal
microflora dominated by pathogenic bacteria is po-
tentially a threat to the patient’s well being. An
abnormal microflora becomes of even greater con-
cern if conditions are present that increase the pa-
tient’s vulnerability.
Vaginitis may be due to infectious or noninfec-
tious causes. Infectious causes present the physican
with a spectrum of etiologic agents including bacte-
ria, fungi, protozoa, and parasites. At times identi-
lying the etiologic agent is simple, while at other
times it is very difficult. Nevertheless, the most
important factor leading to successful treatment is
establishing the correct diagnosis.
MICROBIOLOGY
Understanding the various types of microbial
vaginitis requires an understanding of the microbi-
ology of the healthy vagina. The endogenous mi-
croflora constituting a major part of the vaginal
ecosystem consists predominantly of commensal
bacteria. Potentially pathogenic bacteria, although
in lower concentrations, are also present. The com-
mensal organisms exist in a synergistic state with
one another, but are antagonistic toward the poten-
tially pathogenic bacteria. When environmental
conditions are appropriate, the commensal bacteria
suppress the growth of pathogens.
The dominant bacteria in the healthy vagina are
Lactobacillus, Corynebacterium, and diptheroids.
The pathogenic bacteria consist of gram-positive
and gram-negative aerobes and facultative as well
as obligate anaerobic bacteria. There are many spe-
cies of lactobacilli: L. acidophilus, L. fermentum, L.
brevis, L. casei, L. leichmani, L. salivarious, L.
lactis, and L. cellobiosis.
3 Lactobacilli, especially L.
acidophilus, play a central role in maintaining the
proper environment by producing lactic acid and
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hydrogen perioxide (H202). The pH range of the
healthy vagina is 3.8-4.5, and the proper hydro-
gen ion concentration is maintained through the
production of lactic acid. The pathogenic bacteria,
especially anaerobic bacteria, tend not to grow well
at the healthy pH range. Hydrogen peroxide is
toxic to anaerobic bacteria because they do not pro-
duce catalase and thus cannot convert hydrogen
peroxide to water and oxygen. Hydrogen peroxide
is a bacterial antagonist that functions directly on
the bacterial cell or a peroxidase mediate enzymatic
system. 4’5 Eschenbach et al.
6 demonstrated that
96% of women with a healthy vaginal flora have
hydrogen peroxide-producing lactobacilli. On the
other hand, they found that only 35% of women
with a diagnosis of bacterial vaginosis had lactoba-
cilli, ofwhich only 11% produced hydrogen perox-
ide.
Lactobacilli also produce lactocins which are pro-
tein-inhibiting bacteriocins.
7 These inhibitors have
a narrow spectrum of activity that includes the
strains from which they were produced.
8 These
bacteriocins are an effective means of controlling
bacterial growth. They also maintain lactobacilli
counts within a range that prevents them from ex-
erting an adverse effect on the host. They are lim-
ited in their activity in that some are effective only
against gram-positive bacteria and others only
against gram-negative bacteria.
9 Data suggest that
lactobacilli may inhibit bacterial adherence to epi-
thelial cells,
0,1 which is a significant factor in
view of the fact that the infectious potential of bac-
teria depends upon their ability to adhere to epithe-
lial cells.
The maintenance of the vaginal microecosystem
is dependent upon the dynamic interaction of bacte-
ria and host factors. An important aspect of this
equilibrium concerns the synergism and antago-
nism occurring in the endogenous microflora of the
lower genital tract. Organisms introduced from the
exogenous environment must overcome endogenous
organisms in order to disrupt the equilibrium of
this microecosystem. However, when Neisseria
gonorrhoeae or Chlamydia trachomatis are introduced
in the lower genital tract, the endogenous factors
become significant because these organisms do not
reside in the vagina and infect the more vulnerable
columnar epithelium of the endocervix rather than
squamous epithelial cells.
PATIENT EVALUATION
The initial step in the evaluation of the patient with
a complaint of vaginitis is to obtain a detailed his-
tory. This step is critical in the necessary consider-
ation of all possible factors that may impinge upon
the vaginal microecosystem and disrupt the equi-
librium of the healthy state. This delicate equilib-
rium can easily be disturbed by endogenous or
exogenous factors.
The physician should elicit information regard-
ing the patient’s hygienic practices, change in soaps,
douching agents and frequency, and type, dosage,
and frequency of any medications. Antibiotics
have been shown to alter the endogenous flora.
Cephalosporins, e.g., in a single dose, have been
shown to cause an increase in colonization by en-
12 terococcl.
Determining how sexually active the patient is is
significant because an increase in prevalence of bac-
terial vaginosis has been associated with an increased
frequency of sexual intercourse. Also important to
determine is whether the patient’s pattern of sexual
behavior or practices provide an opportunity for
vaginal colonization by oral or fecal flora. These
bacteria may present a synergistic opportunity when
placed in the same environment with endogenous
pathogens, thereby becoming the dominant flora.
The patient should be given the opportunity to
describe her symptoms in detail, characterize the
discharge, and specifically point out the anatomic
site of her symptoms. Often times, if the patient
does not specifically describe and locate her symp-
toms, the physician and the patient mistakenly pre-
sume that she has a vaginitis. She may believe that
she has a vaginal infection yet identify the location
of her discomfort (usually burning, itching, or
pain) at the opening of the vagina or she may reveal
that she has dyspareunia on insertion of the penis.
Other important information is when the condi-
tion first occurred and specific treatments that have
been used. Knowing the duration of the disease and
treatments already administered will help the phy-
sician to explain the complexity of the problem to
the patient. At the same time, the characteristics of
a healthy vagina should be explained to the patient
(Table 1).
Typically, the patient with a healthy vagina has a
slate-gray to white discharge with no odor. The
estrogenized vagina normally is pink-white with
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TABLE I. Characteristics of a healthy vagina
pH Range 3.8-4.5
Discharge Liquid to creamy-pasty
Color Slate-gray to white
Odor None
Background Free-floating bacteria, mostly bacilli
WBCs Rare
rugae. The presence of petechial hemorrhages on
the vaginal epithelium indicates an abnormal vagi-
nal microecosystem. The presence of an odor ema-
nating from the pelvic area may not originate in the
vagina but may indicate poor hygiene, hidradeni-
tis, or fecal soiling.
The vaginal discharge should be examined mi-
croscopically by swabbing the lateral vaginal wall
with a cotton-tipped swab. The swab is then in-
serted into a tube containing approximately 2 ml of
saline and swirled to dilute the vaginal discharge. A
drop or two of the diluted discharge is placed on a
glass slide and a coverslip is placed over the speci-
men. The specimen should be examined at x40
magnification. The healthy vaginal discharge will
contain squamous epithelial cells whose cytoplasmic
and nuclear membranes are easily seen. Bacteria
will be individually free floating in the vaginal
fluid and will be largely bacillary morphotypes of
equal size (lactobacilli). There may be a rare white
blood cell (WBC).
The pelvic examination should begin with a close
inspection of the vulva to determine the presence of
lesions, e.g., pyodermas, folliculitis, carbuncles,
hidradenitis, raised white pyriform growths, raised
umbilicate lesions, ulcers, erythema, or excoria-
tions. If there is any suggestion that the patient may
have HPV, then later, after the vagina has been
evaluated, the vulva should be painted with 5%
acetic acid and examined under magnification. The
Bartholin’s and Skene’s glands should be palpated
and an attempt made to express the contents of these
glands. If a purulent discharge is present, it should
be Gram stained and cultures should be taken for
aerobic, facultative, and obligate anaerobes as well
as C. trachomatis. A vaginal speculum should be
inserted with care to avoid traumatizing the cervix,
which is likely to result in bleeding if the cervix is
inflamed. The pH of the vagina should be ascer-
tained by applying pH paper to the lateral vaginal
wall. Both semen and spermicides will cause the
pH to be more alkaline, so it is prudent to deter-
mine if the patient has had sexual intercourse in the
preceding 24 hr and if a spermicidal gel has been
used. By performing a microscopic examination of
a diluted specimen of the .vaginal discharge, the
physician should be able to determine whether the
vaginal microecosystem is healthy or not (Table 2).
After performing the pelvic examination, the
physician should be in a position to construct a
differential diagnosis (Table 3). Following the mi-
croscopic examination of the vaginal discharge, a
definitive diagnosis will be possible in most cases.
On occasion, the examination will not reveal the
etiology of the patient’s problem and specialized
testing such as cultures for Candida or Trichomonas
may be necessary.
In 75-80% of the cases, T. vaginalis can be
diagnosed by microscopic examination of the vagi-
nal discharge. The organism is easily identified by
the motile anterior flagella and characteristic move-
ment on microscopic examination of an unstained
preparation of diluted vaginal discharge. The vag-
inal discharge in itself does not possess any specific
characteristics that aid the physician in establishing
a diagnosis without further analysis. A frothy, dirty-
gray discharge can be seen with a trichomonas in-
fection as well with bacterial vaginosis or Gardner-
ella vaginalis. The classic "strawberry cervix" is
seen in only approximately 25% of cases. If there is
strong suspicion of trichomoniasis but no identifi-
able trichomonads, a portion of the vaginal dis-
charge can be placed into a commercial system for
trichomonas culture to allow the trichomonads to
grow. This culture should be examined daily for
the presence of trichomonads. Trichomonads can
also be identified on a Pap smear. Typically, the
bacterial flora will have shifted from lactobacillus-
dominated flora to a polymicrobial one toward
anaerobes.
The presence of trichomonads should alert the
physician that the patient is at risk for other sexually
transmitted organisms and that further testing may
be indicated. A patient with trichomoniasis may
also have a concomitant bacterial vaginosis. In such
a patient, treatment with metronidazole will often
be effective in correcting both infections. Occa-
sionally, a patient may have a concomitant candidi-
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TABLE 2. Characteristics of vaginal discharge
Healthy Bacterial Gardnerella Trichomonas Candida Atrophic
Characteristic vagina vaginosis vaginalis vaginalis vaginitis vaginitis
pH 3.8-4.5 >4.5 >4.5 >4.5 <5 > 3.8
Color Gray-white Gray Gray Gray White White-yellow
Odor None Fishy Fishy Foul None None
Whiff test Negative Positive Positive Positive Negative Negative
Clue cells Negative Positive Positive Negative Negative Negative
Background Bacilli Mixed Clumps Mixed Bacilli Rare
WBCs Rare + Rare Yes Yes Yes
Bacteria Bacilli Mixed Bacilli Mixed Bacilli Rare
TABLE 3. Differential diagnosis for vulvovaginitis
due to infection
Vulva Vagina
Candida Bacterial vaginosis
Folliculitis Gardnerella vaginalis
Carbuncles Streptococcus agalactiae
Hidradenitis Herpes simplex
Herpes simplex Human papillomavirus
Human papillomavirus Trichomonas vaginalis
asis that can usually be detected on a wet-mount
preparation. If difficulty is encountered in identi-
fying pseudohyphae, yeast, or budding yeast forms,
a drop or two of the vaginal discharge can be mixed
with a drop or two of 10% potassium hydroxide
(KOH). The chitinous cell walls of the fungi,
which are resistant to strong alkaline solutions, will
not dissolve as the squamous epithelial and bacterial
cells will.
A microscopic examination of the patient’s vagi-
nal discharge may not reveal the presence of trich-
omonads. However, if it contains a significant num-
ber of WBCs and numerous bacteria of various
morphotypes, but no clue cells or pathogens, a
culture of the discharge specimen should be taken
for T. vaginalis. Consideration should also be given
to the possibility of an I-IPV infection.
Some debate concerns the issue ofwhether bacte-
rial vaginosis is different from G. vaginalis vagini-
tis or whether the latter is just a marker organism
for bacterial vaginosis. Additional so-called marker
organisms are Mycoplasma and Mobiluncus. A re-
view of the original works ofGardner and Dukes
13
makes it apparent that these two conditions may not
be the same or may represent a spectrum of the
same condition. These authors described clue cells
as the presence of gram-negative bacteria (G. vagi-
nalis) adhering to squamous epithelial cells. Their
photomicrographs show that the bacteria in the vag-
inal fluid not attached to squamous epithelial cells
are not individually free floating but clumped or in
aggregates with a characteristic lack of WBCs. G.
vaginalis is a constant factor in the bacteriological
assessment of bacterial vaginosis, as it is usually
present in significant numbers. Perhaps the two
conditions should be viewed as a spectrum of bacte-
rial vaginitis. In the initial phase when the environ-
ment is in the stage of being disrupted, a decline in
lactobacilli occurs resulting in a shift in hydrogen
ion concentration and allowing the growth of G.
vaginalis. The continued growth of G. vaginalis
results in further decline in the hydrogen ion con-
centration and growth of the anaerobes. This con-
tinual decline in hydrogen ion concentration favors
the growth of anaerobes, eventually leading to the
typical microbiological flora of bacterial vaginosis.
This hypothesis has some support in the clinical
setting by observing patients who have been repeat-
edly treated with metronidazole but have failed to
be cured. Microbiological analysis of the vaginal
flora of these patients makes it possible to divide
them into 2 groups: 1) those with nondescript flora
dominated by Staphylococcus epidermidis, Enterococ-
cus faecalis, or Escherichia coli and 2) those with
flora dominated by G. vaginalis and a conspicuous
absence of anaerobes.
14,15 Therefore, it would seem
logical that patients in the early development of a
derangement of the vaginal microflora dominated
by G. vaginalis, which is typically resistant to met-
ronidazole, would not be cured by this drug.
Individuals presenting with a clinical picture of
bacterial vaginosis or G. vaginalis should not have
their vaginal specimens sent for culture if the labo-
ratory is not-equipped to perform a thorough
workup. The treatment options are limited and
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chosen empirically. Patients with repeated or
chronic vaginitis should be thoroughly evaluated
with specimens obtained for the culture of fungi,
trichomonads, Streptococcus agalactiae, and, if labo-
ratory capabilities exist, aerobic, facultative, and
obligate anaerobes. Again, if the laboratory is not
equipped to carry out these studies, obtaining these
specimens will be a waste of money. If vaginal
specimens are sent to the laboratory, they must be
transported in anaerobic vessels. Sending only aer-
obic specimens will usually result in reports of a
single organism, e.g., E. coli. This manner of
handling specimens usually leads to treatment with
an inappropriate antibiotic and failure of the patient
to respond. It is extremely important that, when a
patient complains of recurrent vaginitis, the physi-
cian take time to examine the genital area thor-
oughly and specifically avoid administering anti-
microbial agents that may have an adverse effect on
the vaginal flora and result in continuation of the
patient’s symptoms.
Yeast cells are commonly seen in the patient’s
vaginal fluid, being isolated from approximately
40% of asymptomatic patients with a healthy vagi-
nal microflora.
16 There has been much discussion
regarding the development of more specific and
sensitive tests for the identification ofyeast forms in
patients with complaints of vaginitis. Approxi-
mately 75% of cases can be diagnosed by micros-
copy and KOH. The rapid tests that have been
developed are only about 81% effective. Typically,
the patient with a yeast vaginitis will present with
complaints of vulvovaginal itching. Inspection of
the vulva may or may not reveal the presence of
erythema and excoriation. The vaginal epithelium
as well as the cervical epithelium are erythematous.
The discharge is classically thick and pasty, often
referred to as "cottage cheese-like," but it may be
homogenous and liquid. Usually, no odor is
present, but when present it typically has the aro-
matic odor of yeast. Microscopic examination of a
diluted portion of the vaginal discharge may reveal
the presence of elliptical yeast cells that refract light
and tend to have a greenish tinge to the cytoplasm.
The cells may be budding or have short germina-
tion tubes, which represent the beginning of the
production of the characteristic pseudohyphae.
When the pseudohyphae are quite long and branch-
ing, they can usually be found among clumps of
squamous epithelial cells. In the event that these
structures cannot be identified, an aliquot of vagi-
nal discharge can be placed on a glass slide and or
2 drops of 10% KOH can be added to it. Fungal
and yeast cell walls are made of chitin and resistant
to strong alkaline solutions. Therefore, all non-
chitinous structures, e.g., bacteria and squamous
cells, will dissolve in the alkaline solution. The
remaining fungal cells are easy to identify. In re-
current cases or in cases in which the organisms are
not visually identified, a culture is recommended.
Such a culture can easily be accomplished by plac-
ing a specimen of the vaginal discharge on Sab-
ouraud’s or Nickerson’s medium. In recalcitrant
cases, the organism should be identified according
to species. Antifungal sensitive studies may need to
be performed in patients having tried without suc-
cess all vaginal and oral preparations commonly
used.
TREATMENT
The first error in the management of vaginitis oc-
curs when an antimicrobial agent, even if nothing
more than a sulfa-based cream, is administered to
the patient presenting with vaginitis. If the etiology
of the vulvovaginitis has not been found, it is more
appropriate to try to correct the pH if it is not
within the acceptable range (3.8-4.5) than to pre-
scribe an antimicrobial agent. Perhaps the patient
should do no more than douche with vinegar water.
Again, it is critical to establish the precise location
of the symptoms.
Patients whose complaints are truly localized to
the inferior aspect of the vestibule, specifically the
posterior fourchette, should be first managed by
attempting to establish whether the problem is
chronic inflammation, vestibulitis, or HPV, or a
combination of these conditions. The diagnosis can
be established by performing colposcopy and bi-
opsy of the affected area. Patients with chronic
inflammation are best managed by the local appli-
cation ofhydrocortisone, 1% or 2.5% lotion, cream,
or ointment. Although this therapy can be insti-
tuted prior to performing a colposcopically directed
biopsy, it can cause inconvenience and unnecessary
cost to the patient if a return visit is necessary to
continue the evaluation. A patient with vestibulitis
requires histologic confirmation of her condition.
The tissue typically reveals replacement ofthe gland
acini (vestibular glands) with stratified squamous
epithelium and inflammatory cells. Treatment in-
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volves surgically excising the vulvar tissue contain-
ing the vestibular gland.
17-21 In some instances,
the patient may have either of these diagnoses asso-
ciated with the presence of an HPV infection, in
which case laser ablation may be of value. Prior to
instituting any form of treatment, however, the
presence of other possible causes of vulvar discom-
fort such as herpes or lichen planus must be ruled
out.
The treatment of T. vaginalis is best accom-
plished with oral metronidazole. Intravaginal met-
ronidazole should not be used alone as it is not
effective in eradicating trichomonads found, in the
bladder, upper genital tract, or Skene’s glands.
Therefore, oral preparations should be used. The
only drug approved in the United States is metron-
idazole. Trinidazole, which can be obtained in other
countries, has a longer half-life. A single oral 2-g
dose of metronidazole has been shown to be 90%
effective. If the sexual partner is treated at the same
time, the effectiveness is 95%. z2’z3 This drug can
also be administered in dosages of 250 mg 3 times
daily or 500 mg twice daily for 7 days. The most
common side effects are metallic taste, nausea, and
vomiting. Patients should be strongly advised not
to consume alcoholic-containing liquids while tak-
ing this medication and should refrain from them
for 24 hr after the final dose. The combination of
metronidazole and alcohol produces a disulfiram-
like reaction with nausea and abdominal cramp-
ing.
24
There is some concern over the carcinogenic
potential of metronidazole, which is related to the
detection of mutagens in the urine of patients tak-
ing this drug.
25 These weak carcinogens have been
reported to cause alterations in DNA. Thus far, no
large studies have addressed this concern, but two
small studies have shown no documented relation-
ship between metronidazole use and cancer. 26’27 In
cigarette smokers who have used metronidazole, a
10-fold increase in lung cancer has been reported.
26
Metronidazole is relatively contraindicated in
the pregnant patient. The role of trichomoniasis in
adverse pregnancy is undergoing intensive investi-
gation. This antibiotic does not appear to have ter-
atogenic effects. However, in two relatively small
studies, congenital anomalies were found in infants
born to women who ingested metronidazole in the
first trimester. 26’28 Because of its possible teratoge-
nic and carcinogenic effects, metronidazole should
not be given in the first trimester and should be
used cautiously in the second and third trimes-
ters.
28 Treatment should be reserved for only those
individuals who are truly symptomatic. An alterna-
tive to metronidazole is clotrimazole. Clotrimazole
can inhibit the growth of.T. vaginalis,
29 but it will
not eradicate the trichomoniasis and the infection
will recur.
Women who are breast feeding must be advised
that metronidazole achieves detectable levels in
breast milk.
3 For this reason, breast-feeding
women who must be treated for symptomatic infec-
tion should pump their breasts and discard the milk
for at least the first 24 hr after discontinuing met-
ronidazole. An appropriate course of management
for the breast-feeding patient being treated for tri-
chomoniasis is to collect an adequate supply of breast
milk before instituting metronidazole therapy; dis-
continue breast feeding but pump the breasts; take a
single 2-g dose; and resume breast feeding 24 hr
after completion of therapy.
Any patient who fails routine treatment regi-
mens should be questioned to determine the degree
of her compliance in taking the medication as di-
rected. In addition, any possibility of reinfection
should be pursued. Reinfection can occur if her
partner did not take the medication or she acquired
a new partner. Although T. vaginalis has remained
relatively sensitive to metronidazole, resistant
strains have been reported.
31 Sensitivity testing to
metronidazole is complicated by the possibility that
the test was not conducted in a truly anaerobic
environment, as resistance has not been demon-
strated in a truly anaerobic environment.
31,32 Ox-
ygen has been shown to affect the efficacy of met-
ronidazole.
33 Therefore, since the vaginal
ecosystem is complex, the oxygen reduction poten-
tial of the vaginal ecosystem will undoubtedly have
a significant effect on the effectiveness of the drug
in the treatment of trichomoniasis. Resistant or
chronic infection can be treated by increasing the
dose of metronidazole. One regimen is the admin-
istration of 2-3 g orally daily for 14 days with the
concomitant use of 500 or 1,000 mg vaginal sup-
positories daily or intravaginal metronidazole 2-3
times a day for 14 days. Utilization ofhigh doses of
metronidazole will, in all likelihood, cause signifi-
cant nausea. One investigator reported that strains
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of T. vaginalis with an aerobic MIC >400 mg
required a total of 40 g of metronidazole over a
14-day treatment course. 32’33 Some patients have
also been treated with intravenously administered
metronidazole, 3-4 g/day.
34 However, it must be
pointed out that the administration of metronida-
zole at or above 4 g involves significant potential
for the induction of seizures and disabling periph-
eral neuropathy.
Treatment of yeast vaginitis can be carried out
with a number of antimycotic agents that can be
placed in the vagina either in suppository form or
as a cream. These agents are primarily azole deriv-
atives: butoconazole, clotrimazole, miconazole, and
terconazole. The duration of therapy ranges from 3
to 7 days. Candida albicans is the most common
cause of yeast vaginitis and remains sensitive to the
azoles. However, C. glabrata and C. tropicalis both
tend to be resistant to most azoles, with terconazole
having good activity against these species. 35’36 An-
other effective treatment is nystatin (polyene), but
it should be considered a second-line agent because
it has not produced the success that the azoles have
achieved. Another polyene commonly used in sys-
temic fungal infections is amphotericin B, which is
also supplied as a 3% cream or ointment. It is
typically used for cutaneous or mucocutaneous in-
fection and has not been approved for vaginitis.
Although amphotericin B can be utilized for chronic
or recurrent infection, it should be used with cau-
tion as no data are currently available on its sys-
temic absorption.
Other forms of therapy that have been used with
success are boric acid suppositories, 600 mg, placed
intravaginally twice daily for 10-14 days. Boron
has not been detected in the bloodstream following
intravaginal usage, but it should not be used in
pregnancy because no studies have been conducted
on pregnant patients.
37 Gentian violet used as tab-
lets, paint, or tampons has proven to be effective,
but it is somewhat difficult to use because it stains
the clothing and skin.
Oral therapy has been shown to be effective with
ketoconazole, 400 mg/day for 14 days, followed by
a maintenance dose of 100 mg/day for 6-12 months.
The patient’s liver function must be monitored be-
cause liver toxicity in patients using ketoconazole
for long periods is possible. Fluconazole can also be
given orally, but there is no indication of it in the
treatment of vaginal candidiasis. The dosage has
not been established, but I have had success with an
initial dose of200 mg followed by 100 mg daily for
7 days.
Patients with recurrent or chronic infection
should be evaluated for any underlying systemic
illness such as diabetes or immunodeficiency.
Again, a thorough history is important, especially
with regard to any antimicrobial therapy that the
patient may be on. The patient’s hygiene and sexual
behavioral patterns should be reviewed. In addi-
tion, the possibility of gastrointestinal colonization
should be considered as significant colonization of
the gastrointestinal tract and oral cavity has been
reported in patients with recurrent or chronic in-
fection.
37 Thus far, the available data do not indi-
cate that oral nystatin is beneficial in these patients
over a long period. The data do indicate a benefit
over the short term.
38 The possibility that the or-
ganism may colonize the sexual partner who, in
turn, reintroduces the organism to the vagina of the
patient with each subsequent intercourse should also
be considered. Studies have demonstrated that ap-
proximately 20% of the male sexual partners of
women with candidiasis are colonized.39’4 For this
reason, it is probably beneficial to treat the male
partner with an agent such as fluconazole while
treating the patient. I prefer an oral regimen over a
topical one because the urethra may be colonized.
Treatment of bacterial vaginosis has rested
mainly with the use of metronidazole similar to the
regimens used for the treatment of trichomoniasis.
However, I believe that this agent should be used
only for the first episode. If the patient fails to
respond, consideration should be given to the pos-
sibility that the infection may be in the early stages
of development with the flora dominated by G.
vaginalis, as discussed earlier. Alternative therapy
consists of the use of metronidazole gel or clin-
damycin cream. Oral clindamycin, 3 00 mg twice a
day for 7-10 days, has been shown to be effec-
tive.
41 Other agents that can be used are amoxicillin/
clavulanic acid, 500 mg given orally 3 times daily
for 7-10 days. Ampicillin and amoxicillin have
been shown to be only 30-45% effective in the
treatment of bacterial vaginosis.
49 This observation
is compatible with the hypothesis that this disease
may well be a spectrum of microbiological change
that begins with a decrease in lactobacilli, a rise in
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pH, and an increase in G. vaginalis growth. Treat-
ment at this stage would most likely be effective
since G. vaginalis is sensitive to these agents but
resistant to metronidazole. Once the condition has
progressed and the anaerobes have become domi-
nant, the narrow-spectrum penicillins become inef-
fective.
SUMMARY
Vaginitis due to "infection" can be defined as a
disturbance in the microecosystem in which the
endogenous microflora is prevented from main-
taining its equilibrium. Commensal organisms ex-
ist in a synergistic state with one another and exert
an antagonistic effect on potential pathogens. This
disruption of the dynamic equilibrium of the
healthy vagina may have significant sequelae. These
patients may develop significant symptoms that pre-
vent them from leading normal lives, often pre-
cluding them from having sexual relations because
of odor or pain, and strain their relationships as a
result. In some cases, these patients become "pelvic
cripples." Another concern is the potential for de-
veloping serious conditions such as premature rup-
ture of amniotic membranes, premature labor and
delivery, or low birth weight when vaginitis is
associated with pregnancy. Finally, vaginitis may
predispose a patient undergoing pelvic or vaginal
surgery to significant postoperative infection. For
these reasons, the patient with vaginitis must always
be taken seriously, the condition must never be
written off as a mild insignificant condition, and an
accurate diagnosis must always be established.
REFERENCES
1. Paavonen J, Stamm WE: Lower genital tract infections in
women. In Hansfield HH (ed): Sexually Transmitted
Diseases. Infectious Disease Clinics of North America.
Philadelphia: W.B. Saunders, pp 179-198, 1987.
2. Thomason JI, Gelbart SM, Broekhuizen FF: Office and
clinical laboratory diagnosis of vulvovaginal infections:
An overview. In Horowitz BJ, Mardh P-A (eds): Vagini-
tis and Vaginosis. New York: Wiley-Liss, pp 93-108,
1991.
3. Mardh P-A: Vaginal microbial ecology. In Horowitz BJ,
Mardh P-A (eds): Vaginitis and Vaginosis. New York:
Wiley-Liss, pp 1-9, 1991.
4. Dahiya RS, Speck ML: Hydrogen peroxide formation by
lactobacilli and its effect on Staphylococcus aureus. J Dairy
Sci 51:1568-1572, 1968.
5. KlebanoffJJ, Smith DC: Peroxidase-mediated antimicro-
bial activity of rat uterine fluid. Gynecol Invest 1:21-30,
1979.
6. Eschenbach DA, Davick PR, Williams BC: Prevalence
of hydrogen peroxide producing Lactobacillus species in
normal women and women with bacterial vaginosis. J
Clin Microbiol 27:251-256, 1989.
7. Upreti GC, Hinsdill RD: Isolation and characterization
of a bacteriocin from a homofermative lactobacillus. An-
timicrob Agents Chemother 4:484-487, 1973.
8. Andersson RE, Daeschel MA, Hassan HN: Antibacte-
rial activity of plantaricin SIK-83, a bacteriocin produced
by Lactobacillus plantarum. Biochemistry 70:381-390,
1988.
9. Barefoot SK, Klaenhammer TR: Detection and activity
of lactacin B, a bacteriocin produced by Lactobacillus
acidophilus. Appl Environ Microbiol 45:1808-1815,
1983.
10. Reid G, Cook RL, Bruce AW: Examination of strains of
lactobacilli for properties that may influence bacterial in-
terference in the urinary tract. J Urol 138:330-335,
1987.
11. Sobel JD, Myers P, Levison ME, Kaye D: C. albicans
adherence to vaginal epithelial cells. J Infect Dis 143:
767-782, 1981.
12. Cox SM, Phillips LE, Mercer LJ, Stager CE, Waller S,
Faro S: Lactobacillemia of amniotic fluid origin. Obstet
Gynecol 68:134-135, 1986.
13. Gardner HL, Dukes CD: Haemophilus vaginalis vagini-
tis. Am J Obstet Gynecol 69:962-976, 1955.
14. Faro S, Phillips LE: Non-specific vaginitis or vaginitis of
undetermined etiology. Int J Tissue Reactions IX:173-
177, 1987.
15. Faro S: Persistent vaginitis and vaginosis. In Horowitz
BJ, Mardh P-A (eds): Vaginitis and Vaginosis. New York:
Wiley-Liss, pp 237-245, 1991.
16. Sobel JD: Epidemiology and pathogenesis of recurrent
vulvovaginal candidiasis. Am J Obstet Gynecol 152:924-
935, 1985.
17. Friedrich EG Jr: Vulvar vestibulitis syndrome. J Reprod
Med 32:110-114, 1987.
18. Pyka RE, Wilkinson EJ, Friedrich EG Jr, Croler BP:
The histopathology of vulvar vestibulitis syndrome. Int J
Gynecol Pathol 7:249-257, 1988.
19. Turner MLC, MarinoffSC: Association ofhuman papil-
loma virus with vulvodynia and the vulvar vestibular
syndrome. J Reprod Med 33:533-537, 1988.
20. Friedrich EG Jr: Therapeutic studies on vulvar vestibuli-
tis. J Reprod Med 33:514-518, 1988.
21. Woodruff D, Friedrich EG Jr: The vestibule. Clin Ob-
stet Gynecol 28:134-141, 1985.
22. Lossick JG: Treatment of Trichomonas vaginalis infec-
tions. Rev Infect Dis 4:S-801-818, 1982.
23. Hager WD, Brown ST, Klaus SJ, et al.: Metronidazole
in vaginal trichomoniasis. Seven day vs. single-dose re-
gimes. JAMA 244:1219-1220, 1980.
24. O’Reilly RA: Stereospecific interaction of warfarin and
metronidazole. Fed Proc 34:259, 1975.
160 INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGYREVIEW OF VAGINITIS FARO
25. Roe JFC: A critical appraisal of the toxicology of metron-
idazole. In Phillips I, Collier J (eds): Metronidazole.
London: Academic Press, pp 215-222, 1979.
26. Beard CM, Noller KL, O’Fallon WM, Kurkland LT,
Dockerty MB: Lack of evidence for cancer due to use of
metronidazole. N Engl J Med 301:519-522, 1979.
27. Friedman GD: Cancer after metronidazole (letter). N
Engl J Med 302:519, 1980.
28. Peterson WF, Stauch JE, Ryder CO: Metronidazole in
pregnancy. Am J Obstet Gynecol 94:343-349, 1966.
29. Erickson SH, Oppenheim GL, Smith GH: Metronida-
zole in breast milk. Obstet Gynecol 57:48-50, 1981.
30. Schnell JD: The incidence of vaginal Candida and Trich-
omonas infections and treatment of Trichomonas vaginalis
with clotrimazole. Postgrad Med 50:79-81, 1974.
31. Pereyra AJ, Lansing JD: Urogenital trichomoniasis.
Treatment with metronidazole in 2,002 incarcerated
women. Obstet Gynecol 24:499-508, 1964.
32. Meingassner JG, Turner J: Strains of Trichomonas vagi-
nalis resistant to metronidazole and other 5-nitro-imida-
zoles. Antimicrob Agents Chemother 15:254-257, 1979.
33. Lossik JG, Muller M, Gorrell TE: In vitro drug suscep-
tibility and doses of metronidazole required for cure in
cases of refractory vaginal trichomoniasis. J Infect Dis
153:948-955, 1986.
34. Muller M, Lossick JG, Gorrell TE: In vitro susceptibil-
ity of Trichomonas vaginalis to metronidazole and treat-
ment outcome in vaginal trichomoniasis. Sex Transm Dis
15:17-24, 1988.
35. Frytak S, Mortel CG, Childs OS, Albers JW: Neuro-
logic toxicity associated with high dose metronidazole.
Ann Intern Med 88:361-362, 1978.
36. Redondo-Lopez V, Lynch M, Schmitt C: Torulopsis gla-
brata vaginitis: Clinical aspects and susceptibility to anti-
fungal agents. Obstet Gynecbl 76:651-655, 1990.
37. Cook CW: Vulvovaginal candidiasis (letter). Obstet Gy-
necol 48:631, 1976.
38. Miles MR, Olsen I, Rogers A: Recurrent vaginal candid-
iasis: Importance of an intestinal reservoir. JAMA 238:
1836-1837, 1977.
39. Nystatin Multicenter Study Group: Therapy of candidal
vaginitis. The effect of eliminating intestinal Candida.
AmJ Obstet Gynecol 155:651-655, 1986.
40. Horowitz BJ, Edelstein SW, Lippman L: Sexual trans-
mission of Candida. Obstet Gynecol 69:883-886, 1987.
41. Greaves W, Chungafung J, Morris B, Haile A,
Townsend JF: Clindamycin versus metronidazole in the
treatment of bacterial vaginosis. Obstet Gynecol 72:799-
802, 1988.
42. Lee L, Schmale JD: Ampicillin therapy for Corynebacte-
rium vaginalae (Haemophilus vaginalis) vaginitis. Am J
Obstet Gynecol 115:786-788, 1973.
INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY